Cancer drug: Dr Reddy's arm faces antitrust complaint in US over Revlimid
Telangana: Dr Reddy’s Laboratories, Inc., a wholly-owned step-down subsidiary of Dr Reddy’s Laboratories Limited, along with several other pharmaceutical companies, have been named as a defendant in a complaint filed on October 6, 2023, in the United States District Court for the Northern District of California."The complaint, filed by Mayo Clinic and Lifepoint Corporate...
Telangana: Dr Reddy’s Laboratories, Inc., a wholly-owned step-down subsidiary of Dr Reddy’s Laboratories Limited, along with several other pharmaceutical companies, have been named as a defendant in a complaint filed on October 6, 2023, in the United States District Court for the Northern District of California.
"The complaint, filed by Mayo Clinic and Lifepoint Corporate Services, asserts claims under federal and state antitrust laws and other state laws alleging that the defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid through their respective settlements of patent litigation," Dr Reddys informed in a BSE filing.
The complaint alleges that the challenged agreements improperly delayed generic entry entirely until 2022 and then improperly limited generic competition through 2026. The complaint seeks damages for purported overpayments and equitable relief. Dr Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation.
Read also: Multiple myeloma drug case: Dr Reddy Labs gets legal respite in US
Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.
Read also: CDSCO Panel Rejects Dr. Reddy's Proposal For Ketorolac Tromethamine plus Serratiopeptidase FDC
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd